Business Context and Reporting Period
This Form 8-K is a current report filed by Catalyst Biosciences, Inc. (not Gyre Therapeutics, Inc.) on September 8, 2021. The filing reports a corporate governance event regarding the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance metrics.
Material Changes
- Board Expansion: The Board of Directors increased its size from seven to eight members, effective September 9, 2021.
- Director Appointment: Ms. Jeanne Y. Jew was appointed as a Class III director. Her term will expire at the 2024 Annual Meeting of Stockholders.
- Compensation: Ms. Jew will receive cash and equity compensation consistent with the company's current practices for non-employee directors and will enter into a standard indemnification agreement.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. No specific risks or contingencies related to the appointment were disclosed beyond standard governance procedures. The Board cited Ms. Jew's significant experience in the biopharmaceutical industry as the rationale for her qualification.
Investor Verification Checklist
- Verify the effective date of the board expansion (September 9, 2021).
- Confirm Ms. Jeanne Y. Jew's tenure as a Class III director through the 2024 Annual Meeting.
- Review the attached press release (Exhibit 99.1) for additional details on the appointment.
- Note that this filing contains no financial data; refer to the most recent 10-Q or 10-K for financial metrics.